

## Special Issue

# Enteroviruses: Advances in Virology, Pathogenesis, and Vaccine R&D

### Message from the Guest Editors

Enteroviruses are a diverse group of RNA viruses within the Picornaviridae family, responsible for various human diseases. Specific serotypes, such as enterovirus-71 (EV-71) and coxsackieviruses, are significant causes of hand, foot, and mouth disease (HFMD). This Special Issue aims to bring together the latest research and scientific advances on enteroviruses, covering virology, molecular epidemiology, viral pathogenesis, immunological responses, and vaccine R&D. Original research articles and reviews are welcome, which research areas may include (but are not limited to) the following:

- Enterovirus classification, phylogenetics, genomic analysis, and evolutionary dynamics
- Molecular and cellular mechanisms of viral pathogenesis
- Surveillance systems, outbreak investigation, and transmission patterns
- Host immune responses and correlates of protection
- Vaccine development and evaluation, especially multivalent (multi-serotype) vaccines and novel platforms such as mRNA and virus-like particle (VLP) technologies
- Epidemiological trends and public health strategies
- Studies focusing on poliovirus, EV-71, coxsackieviruses, and other clinically relevant enteroviruses

---

### Guest Editors

Dr. Yang Song  
Dr. Naiying Mao  
Dr. Jinbo Xiao

---

### Deadline for manuscript submissions

31 October 2026



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/238307](https://mdpi.com/si/238307)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

---

### Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College  
Roosevelt, 4331 CB Middelburg, The Netherlands

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).